Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.37 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238968 | 0.92 | SLC29A1 (0.39) | SLC29A1RXFP1ADORA2AADORA3ADORA1 | |
| SCHEMBL5963100 | 0.88 | STING1 (0.47) | SLC29A1RXFP1ADORA2AADORA3ADORA2B | |
| SCHEMBL15763413 | 0.87 | ACHE (0.38) | SLC29A1RXFP1ADORA2AADORA3ADORA1 | |
| SCHEMBL13030116 | 0.86 | NT5E (0.43) | SLC29A1RXFP1STING1PDE3BPDE3A | |
| SCHEMBL15837352 | 0.86 | RXFP1 (0.37) | RXFP1ADORA2AADORA3ADORA1STING1 | |
| SCHEMBL15763461 | 0.84 | SLC29A1 (0.39) | SLC29A1RXFP1ADORA3ADORA1CYP2C19 | |
| SCHEMBL4757808 | 0.81 | ADORA3 (0.54) | RXFP1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL8594450 | 0.81 | AHCY (0.50) | ADORA2AADORA3ADORA1ADORA2BSTING1 | |
| SCHEMBL19961896 | 0.81 | ADORA3 (0.54) | RXFP1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22216550 | 0.81 | ADORA3 (0.54) | RXFP1ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20160039858-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9249174-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9243022-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20160039858-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | SLC29A1 14/4885RXFP1 4303/4885ADORA2A 78/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC29A1 18/4885RXFP1 4623/4885ADORA2A 47/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | SLC29A1 11/4885RXFP1 3902/4885ADORA2A 57/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | SLC29A1 14/4885RXFP1 4303/4885ADORA2A 78/4885 |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC29A1 5/4885RXFP1 3962/4885ADORA2A 71/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | SLC29A1 11/4885RXFP1 3902/4885ADORA2A 57/4885 |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | SLC29A1 12/4885RXFP1 4140/4885ADORA2A 71/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC29A1 18/4885RXFP1 4623/4885ADORA2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.